Medifast Reports Significant Revenue Decline and Net Loss in Q2 2026

Medifast, Inc. reported a significant decline in financial performance for the second quarter and first half of 2026, as detailed in its latest 10-Q filing. For the three months ended June 30, 2026, the company generated revenue of $76.4 million, a decrease of 27.6% from $105.6 million in the same period of 2025. The six-month revenue also fell by 31.1%, totaling $152.4 million compared to $221.3 million in the prior year. The company experienced a net loss of $3.1 million, or $0.28 per diluted share, for the second quarter, contrasting sharply with a net income of $2.5 million, or $0.22 per diluted share, in the previous year. For the first half of 2026, the net loss was $5.2 million, compared to a profit of $1.7 million in 2025.

The decline in revenue was primarily attributed to a reduction in the number of active earning coaches, which decreased to approximately 11,700 from 22,800 year-over-year. This trend has been ongoing since early 2023 and reflects broader challenges in client acquisition, including increased competition from GLP-1 medications for weight loss. Despite the drop in active coaches, the average revenue per coach increased by 41% to $6,529, indicating improved productivity among the remaining coaches.

Operationally, Medifast has been undergoing a strategic transformation, shifting its focus from traditional weight loss to a broader metabolic health approach. In July 2026, the company launched its new brand, Trilivy, which aims to address metabolic dysfunction affecting a significant portion of the U.S. population. This rebranding is part of a long-term growth strategy that includes enhancing product offerings and expanding the coach network. The company also reported a decrease in selling, general, and administrative expenses, which fell by 25.7% to $57.7 million for the second quarter, largely due to lower coach compensation and marketing costs.

Looking ahead, Medifast anticipates continued challenges in the operating environment, particularly with the ongoing decline in active earning coaches. However, the company remains committed to its transformation strategy and expects to leverage its scientific and clinical heritage to enhance its product offerings. The introduction of the Trilivy Reset Fueling line, designed to support metabolic health, is expected to further strengthen the company's market position. Medifast's management is focused on improving coach productivity and expanding its network, which they believe will drive future growth despite current market pressures.